Cryoport to Report Third Quarter 2021 Financial Results on November 4, 2021
Cryoport (NASDAQ: CYRX), a leader in temperature-controlled supply chain solutions, will report its third quarter 2021 financial results on November 4, 2021, after market close. Accompanying the results, a document titled 'Cryoport Third Quarter 2021 in Review' will be released at 4:05 PM ET. A conference call to discuss the results is scheduled for 5:00 PM ET on the same day. This call will include a Q&A session to address investor queries. The company supports critical cell and gene therapies and has been involved in numerous clinical trials globally.
- Global leader in temperature-controlled supply chain solutions.
- Supports over 2000 active biopharma clients worldwide.
- Involved in 561 regenerative medicine clinical trials globally.
- None.
NASHVILLE, Tenn., Oct. 28, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021 after U.S. markets close.
In addition to the earnings release, a document titled "Cryoport Third Quarter 2021 in Review", providing a review of Cryoport's recent financial and operational performance and a general business update, will be issued at 4:05 pm ET on Thursday, November 4, 2021. The document is designed to be read by investors before the questions and answers conference call and will be accessible at http://ir.cryoport.com/events-and-presentations.
Cryoport management will host a conference call at 5:00 pm ET on November 4, 2021. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany the call.
Conference Call Information | |
Date: | November 4, 2021 |
Time: | 5:00 p.m. EDT |
Dial-in numbers: | 1-800-928-9281 (U.S.), 1-303-223-0118 (International) |
Confirmation code: | Request the "Cryoport Call" |
Live webcast: | 'Investor Relations' section at www.cryoport.com or at: click here |
Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software. | |
Questions and answers will be recorded and available approximately three hours after completion of the live event on the Investor Relations section of the Company's website at www.cryoport.com for a limited time. To access the replay of the questions and answers, please follow this link. A dial-in replay of the call will also be available to those interested, until 11:59 p.m. ET on November 11, 2021. To access the replay, dial +1 844-512-2921 (United States) or +1 412-317-6671 (International) and enter replay pin number: 21998687.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX) is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the clinical and commercial spectrum. With 33 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform consists of a family of businesses (Cryoport Systems, MVE Biological Solutions, CRYOPDP and CRYOGENE), that provide mission-critical solutions, services and products to more than 2000 active biopharma, reproductive medicine and animal health customers worldwide. Cryoport is the world's largest manufacturer of cryogenic equipment and the world's third largest specialty courier to the life sciences industry. As of June 30, 2021, Cryoport supported eight commercial cell and gene therapies and 561 regenerative medicine clinical trials in more than 150 countries. 69 of these trials were in Phase 3.
For more information, visit www.cryoport.com or follow @cryoport on Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, plans, strategy, acquisitions, including CRYOPDP and MVE Biological Solutions, financial results and financial condition. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors discussed in the Company's Securities and Exchange Commission ("SEC") reports including, but not limited to, the Company's Annual Report on Form 10-K for the three and twelve months ended December 31, 2020 and any subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-third-quarter-2021-financial-results-on-november-4-2021-301411462.html
SOURCE Cryoport, Inc.
FAQ
When will Cryoport report its third quarter financial results?
What time is the Cryoport conference call scheduled for?
Where can investors access the Cryoport earnings release?
What document will accompany Cryoport's earnings release?
